1. Home
  2. NGNE vs BRBS Comparison

NGNE vs BRBS Comparison

Compare NGNE & BRBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • BRBS
  • Stock Information
  • Founded
  • NGNE 2003
  • BRBS 1893
  • Country
  • NGNE United States
  • BRBS United States
  • Employees
  • NGNE N/A
  • BRBS N/A
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • BRBS Commercial Banks
  • Sector
  • NGNE Health Care
  • BRBS Finance
  • Exchange
  • NGNE Nasdaq
  • BRBS Nasdaq
  • Market Cap
  • NGNE 325.3M
  • BRBS 326.4M
  • IPO Year
  • NGNE N/A
  • BRBS N/A
  • Fundamental
  • Price
  • NGNE $18.48
  • BRBS $4.02
  • Analyst Decision
  • NGNE Strong Buy
  • BRBS
  • Analyst Count
  • NGNE 7
  • BRBS 0
  • Target Price
  • NGNE $41.86
  • BRBS N/A
  • AVG Volume (30 Days)
  • NGNE 110.1K
  • BRBS 444.7K
  • Earning Date
  • NGNE 08-11-2025
  • BRBS 10-28-2025
  • Dividend Yield
  • NGNE N/A
  • BRBS N/A
  • EPS Growth
  • NGNE N/A
  • BRBS N/A
  • EPS
  • NGNE N/A
  • BRBS N/A
  • Revenue
  • NGNE N/A
  • BRBS $96,787,000.00
  • Revenue This Year
  • NGNE N/A
  • BRBS N/A
  • Revenue Next Year
  • NGNE N/A
  • BRBS N/A
  • P/E Ratio
  • NGNE N/A
  • BRBS N/A
  • Revenue Growth
  • NGNE N/A
  • BRBS 10.13
  • 52 Week Low
  • NGNE $6.88
  • BRBS $2.66
  • 52 Week High
  • NGNE $74.49
  • BRBS $4.14
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 35.93
  • BRBS 63.43
  • Support Level
  • NGNE $19.59
  • BRBS $3.63
  • Resistance Level
  • NGNE $20.46
  • BRBS $4.14
  • Average True Range (ATR)
  • NGNE 1.23
  • BRBS 0.12
  • MACD
  • NGNE -0.20
  • BRBS 0.03
  • Stochastic Oscillator
  • NGNE 13.37
  • BRBS 75.49

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About BRBS Blue Ridge Bankshares Inc.

Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary, Blue Ridge Bank, National Association, and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance and others. It has three reportable business segments: commercial banking, mortgage banking, and holding company activities.

Share on Social Networks: